Focus on Infectious Disease
  • Saved
Preclinical demonstration of a potent, universal coronavirus monoclonal antibody therapy for all COVID-19 variants

Preclinical demonstration of a potent, universal coronavirus monoclonal antibody therapy for all COVID-19 variants

Source : https://www.uab.edu/news/research/item/12714-preclinical-demonstration-of-a-potent-universal-coronavirus-monoclonal-antibody-therapy-for-all-covid-19-variants

The monoclonal antibody cocktail is deliverable via a nasal dose, and it is also effective against SARS, MERS and several coronavirus cold viruses. The antibodies are engineered for long-acting effectiveness,...



“The ability of 1249A8, given as a single dose, to mitigate SARS-CoV-2 pathology and viral burden against all variants of concern tested when used either prophylactically or therapeutically, along with the added benefit of combining with a broad and potent RBD-specific hmAb, substantiate its clinical potential.”

  • Saved
Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages - Mucosal Immunology

Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages - Mucosal Immunology

Source : https://www.nature.com/articles/s41385-021-00482-8

Monocyte-derived macrophages (MDM) drive the inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and they are a major source of eicosanoids in airway inflammation. Here we report that...



Stimulation with SARS-CoV-2 spike protein or LPS triggered exaggerated prostanoid-, type I IFN-, and chemokine responses in post COVID-19 MDM. Thus, SARS-CoV-2 infection leaves an inflammatory imprint in the monocyte/ macrophage compartment that drives aberrant macrophage effector functions and eicosanoid metabolism, resulting in long-term...

  • Saved
Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination

Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination

Source : https://onlinelibrary.wiley.com/doi/10.1002/eji.202149758

Markus Hoffmann , Bernhard Schaaf , Stefan Pöhlmann , Carsten Watzl , Corresponding Author Carsten Watzl Department for Immunology, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at...



Importantly, full COVID-19 vaccination of these individuals resulted in higher antibody titers compared to fully vaccinated individuals in the absence of prior infection. These data demonstrate long-lived antibody-mediated immunity after SARS-CoV-2 infection, and a clear benefit of two vaccine doses for recovered individuals.

  • Saved



Conclusions and Relevance: Among pregnant and postpartum individuals at 17 US hospitals, SARS-CoV-2 infection was associated with an increased risk for a composite outcome of maternal mortality or serious morbidity from obstetric complications.

  • Saved
OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)

OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)

Source : https://ard.bmj.com/content/80/Suppl_1/173.2

Background: An increased risk of severe COVID-19 outcomes may be seen in patients with autoimmune diseases on moderate to high daily doses of glucocorticoids, as well as in those with...



Conclusion: Increased age, male sex, glucocorticoid use, chronic renal disease, cardiovascular disease and moderate/high disease activity at time of COVID-19 diagnosis were associated with more severe COVID-19 outcomes in SLE. Potential limitations include possible selection bias (physician reporting), the cross-sectional nature of the data,...